ASSESSMENT OF VISFATIN IN IRAQI WOMEN WITH TYPE 2 DIABETES MELLITUS

Abstract

Diabetes is stated that affects more than 463 million people worldwide today and type 2 diabetes mellitus (T2DM) represents 90-95% of the total instances. In general, the adipokines are categorized into two groups: proinflammatory adipokines” such as visfatin and leptin that promotes insulin resistance and inflammation and “anti-inflammatory adipokines that have the beneficial effect such as adiponectin. Visfatin is one of these hormones (adipokines) that has pro-inflammatory properties and are present in visceral fat tissue. Assessment of visfatin in Iraqi women with type 2 diabetes mellitus. Study patients were recruited from the Al-Yarmouk Teaching Hospital during the period among the “1st of June 2024 to the 1st of September 2024”. 58 patients “32 males and 26 females”, aged ≥ 30 years were consecutively selected from those who were admitted and diagnosed as DM by specialist. The apparently healthy subjects as a controls group were recruited from those who had no current illness with consideration of age and sex matching with patients. It was shown that serum visfatin had a significant difference among study groups (p<0.001), also the baseline mean level was significantly different between patients and controls (P<0.001) Visfatin level had perfect AUC and high sensitivity and specificity for discrimination between patients and controls. The present study found the values of serum visfatin in patients with DM2 patients are significantly higher compared with controls. Adipokine with an insulin-mimetic action that tends to increase insulin sensitivity and reduces blood glucose level and this clarifies the elevated level of Visfatin in such T2DM.